Clinical trials: Covid-19 Patients
SARS-CoV2
Methylene Blue Treatment of COVID-19
Despite enormous progress in understanding COVID-19, there is little evidence that a solution, therapeutic or preventive, is close to being achieved.
- Trial name
- NCT04635605
- Testing
- Methylene Blue, Control Test
- Where
- Switzerland
- Volunteers
- 29 people
- Sponsor
- Fondazione Epatocentro Ticino
COVID-19, Stress Disorders, Post-Traumatic
Psychological Impact of Medical Evacuations on Families of Patients Admitted to Intensive Care Unit for Severe COVID-19
At the "Métropole Savoie" hospital, to deal with the daily influx of severe patients during the second wave of COVID-19, 23 patients had to be transferred away from their home city and far from their families as part of a medical…
- Trial name
- IPES-CoV (NCT05421182)
- Testing
- Revised Impact of Event Scale, Hospital Anxiety and Depression scale, 36-Item Short Form Survey
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Metropole Savoie
COVID-19
Safe and Timely Cessation of Isolation of Patients With COVID-19 (The SCIP-COVID-19) Study
Rationale: In the treatment, care and isolation of COVID-19 patients, one of the most important issues is determining the duration of infectiousness.
- Trial name
- SCIP-COVID19 (NCT05346042)
- Testing
- duration infectiousness
- Where
- Netherlands
- Volunteers
- 7,000 people
- Sponsor
- Anne Voor in 't holt
Myasthenia Gravis
Follow-up of a Cohort of Patients With Myasthenic Syndrome and COVID-19 Infection
Coronavirus disease 2019 (COVID-19), declared by the World Health Organization (WHO) as a "public health emergency of international concern" (January 31, 2020), has posed a significant threat to global health.
- Trial name
- CO-MY-COVID (NCT04695379)
- Where
- 10 sites in France
- Volunteers
- 34 people
- Sponsor
- University Hospital, Bordeaux
Coronavirus Infection
Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia
In early December 2019, cases of pneumonia of unknown origin were identified in Wuhan, China. The causative virus was called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- COP-COVID-19 (NCT04358783)
- Testing
- Plasma, Best Available Therapy
- Where
- Mexico
- Volunteers
- 31 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Pulmonary Fibrosis, Interstitial Lung Disease
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
This is a collaborative study between Icahn School of Medicine at Mount Sinai, Boehringer Ingelheim Pharmaceuticals and up to 9 other clinical centers across the US to determine the effect of nintedanib on slowing the rate of…
- Conditions
- Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease
- Trial name
- ENDCOV-I (NCT04619680)
- Testing
- Nintedanib
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Novel Coronavirus Infectious Disease (COVID-19)
The Clinical Study of Carrimycin on Treatment Patients With COVID-19
The novel coronavirus infectious disease ( COVID-19") induced by novel coronavirus(SARS-CoV-2) in December 2019 has outbreaked in Wuhan. It may lead to epidemic risk in global.
- Trial name
- NCT04286503
- Testing
- Carrimycin, lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate, basic treatment
- Volunteers
- 520 people
- Sponsor
- Beijing YouAn Hospital
Acute Respiratory Distress Syndrome, COVID-19 Pneumonia
Double-blind, Randomized, Controlled Clinical Trial to Assess Efficacy of MSC in Patients With COVID-19 ARDS
A double-blind, randomized, controlled, clinical trial to evaluate the efficacy and safety of MSC (mesenchymal stromal cells) intravenous administration in patients with COVID-induced ARDS compared to a control arm.
- Trial name
- NCT04615429
- Testing
- Mesenchymal stromal cells
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Cristina Avendaño Solá
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Covid19, Hip Arthropathy
The Impact of COVID-19 Pandemic on Hip and Knee Replacement
During the COVID-19 pandemic, the care of patients undergoing hip or knee replacement for osteoarthritis remains a clinical priority.
- Conditions
- Covid19, Hip Arthropathy, Knee Arthropathy
- Trial name
- PTA/PTGCovid (NCT04883788)
- Testing
- Pandemic period
- Where
- Italy
- Volunteers
- 600 people
- Sponsor
- Istituto Ortopedico Rizzoli
COVID-19, Thrombosis Embolism
The Effect of Dexamethasone 12 mg vs 6 mg on Thromboembolic Events in Patients With Critical COVID-19
Thromboembolisms (TEs) in patients with critical COVID-19 has been reported to be three times higher than for other critically ill patients. Immunothrombosis has been proposed as a plausible mechanism for COVID-19 coagulopathy.
- Conditions
- COVID-19, Thrombosis Embolism, Bleeding
- Trial name
- NCT05195242
- Testing
- Dexamethasone
- Where
- Sweden
- Volunteers
- 445 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Long COVID, Post-COVID-19 Condition
Mitochondrial Function in Peripheral Blood Mononuclear Cells, Muscle, and Skin of Long COVID Patients
Mitochondria are structures inside cells that are responsible for producing energy from nutrients through a series of steps, using oxygen.
- Trial name
- MitoLoCo (NCT07134673)
- Where
- Belgium
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Patients With Cancer, Vaccine Reaction
Safety and Immunogenicity of Prime-boost Vaccination of SARS-CoV-2 in Patients With Cancer
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a global pandemic since late 2019 that resulted in more than 360 million population infection.
- Conditions
- Patients With Cancer, Vaccine Reaction, COVID-19
- Trial name
- NCT05273541
- Testing
- Coronavirus vaccination
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Beijing 302 Hospital
Covid19
Recovery of Respiratory System in COVID-19 Patients
The purpose of this study is to determine the effects of the clinical course of treatment as well as long-term symptoms of COVID-19 on respiratory function, exercise capacity, and quality of life.
- Trial name
- NCT04954222
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS
Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab
The primary goal of this study is to provide additional data regarding B and T-cell mediated responses to COVID-19 vaccines in MS patients treated with OCR and to determine which clinical and paraclinical variables correlating…
- Conditions
- Multiple Sclerosis, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System, Nervous System Diseases
- Trial name
- OCR-VAX (NCT04837651)
- Testing
- Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test, T-Detect COVID T-cell blood test
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dragonfly Research, LLC
Coronavirus
Patient Preference Trial for COVID-19 (PPT-COVID)
To date no treatment has proven its effectiveness in the caring of patients infected with type 2 Coronavirus. The Centre Hospitalier Princesse Grace (CHPG) has decided to only propose randomized double-blind placebo-controlled…
- Trial name
- PPT-COVID (NCT04418193)
- Where
- Monaco
- Sponsor
- Centre Hospitalier Princesse Grace
Covid19, SARS-CoV Infection
Caracterisation of COVID-19 Patients Hospitalized in Infectious Disease Department
The main objective of this cohort is to characterize COVID-19 patients hospitalized in infectious disease department. The collection of clinical and biological data from start of hospitalization to long-term follow up will…
- Trial name
- NCT04779021
- Testing
- Hospitalisation for SARS-COV2 infection
- Where
- 2 sites in France
- Volunteers
- 1,300 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
COVID-19 Patients
To Evaluate SSD8432/ Ritonavir in Adults With COVID-19
This is a randomized, double-blind, Phase 1b clinical trial to evaluate the safety, Pharmacodynamics, and Pharmacokinetic of SSD8432 combined with ritonavir tablets in adults with COVID-19.
- Trial name
- NCT05369676
- Testing
- SSD8432 dose 1/Ritonavir, SSD8432 dose 2/Ritonavir
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Covid19, Corona Virus Infection
Expanded Access to Zofin for Patients With COVID-19
This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider…
- Conditions
- Covid19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), Acute Respiratory Distress Syndrome
- Trial name
- NCT04657406
- Testing
- Zofin
- Sponsor
- ZEO ScientifiX, Inc.
Mortality, Intensive Care Unit
Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit
Effect of Favipiravir and Lopinavir-Ritonavir on Mortality in a Tertiary Center Intensive Care Unit: Single Center Experience
- Trial name
- NCT04645433
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.